OneMedNet Corp
ONMDOneMedNet Corp in brief
OneMedNet Corp is a listed company in the Diagnostics and Research industry, based in the UK. Its market value was $237 M on 14 October 2026, which makes it the 15,648th largest listed company in the world and the 504th largest in the UK on this site. In the year to December 2025 it had sales of $1 M and a net loss of $3 M. Its largest product and service lines by sales in 2025 were Data Delivery Revenue (92%) and Subscription Revenue (8%). By market, the largest shares of its 2025 sales came from EMEA (51%), Americas (45%) and Asia Pacific (4%). Its shares trade under the symbol ONMD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About OneMedNet Corp
OneMedNet is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data. OneMedNet’s innovative solutions connect healthcare providers and patients satisfying a crucial need within the life sciences field offering direct access to clinical images and the associated contextual patient record. OneMedNet’s innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet’s life science partners case selection protocols and paves the way for Real World Evidence (as defined below).
From the company's annual report filed with the US SEC: read the report
OneMedNet Corp timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering as Data Knights Acquisition Corp.Final prospectus filed with the SEC on 10 May 2021; shares registered for exchange trading on 5 May 2021. The blank-check company later merged with the business that carries the name today.
- 2023
- ✎Renamed OneMedNet CorpFormerly Data Knights Acquisition Corp..
- 2025
- 💰Record revenue of $1 millionFY2025, the highest of the 4 years on record.
Events of OneMedNet Corp from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 163.6×
- Price / book
- —
- Free cash flow yield
- -3.2%
- Net margin (TTM)
- -586.2%
- Operating margin
- -711.0%
- Return on equity
- —
- Liabilities / assets
- 238.1%
- Net debt
- $-0M
- Revenue growth
- +112.5%
- R&D / revenue
- 111.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | +112.5% | $-10M | $-3M | -205.9% |
| Dec 2024 | $1M | -37.3% | $-10M | $-10M | -1582.8% |
| Dec 2023 | $1M | -11.3% | $-7M | $-34M | -3311.8% |
| Dec 2022 | $1M | — | $-8M | $-30M | -2647.8% |
| Dec 2021 | — | — | $-1M | $5M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | $0M | $-8M | $-0.06 | — |
| Dec 2024 | $-7M | $0M | $-7M | $-0.36 | — |
| Dec 2023 | $-5M | $0M | $-5M | $-4.65 | — |
| Dec 2022 | $-5M | $0M | $-5M | $-7.66 | — |
| Dec 2021 | $-0M | — | — | $0.44 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $0M (+81.2% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 9, 20268-KCurrent reportResults of operations
- Nov 6, 20268-KCurrent reportResults of operations
- Oct 14, 20268-KCurrent reportOther events
- Sep 29, 20268-KCurrent reportBylaws amended
- Sep 23, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Aug 19, 2026DEF 14AProxy statement
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 24, 20268-KCurrent reportOther events
- Jul 8, 2026S-1/AIPO registration (amended)
- Jul 1, 2026S-1IPO registration
- Jul 1, 20268-KCurrent reportMaterial agreement
- May 15, 202610-QQuarterly report · period to Mar 2026
Official filings of OneMedNet Corp with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-10 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $2 M
- Total liabilities
- $5 M
- Total equity
- $-3 M
As of December-2025
Top 13 institutional investors in OneMedNet Corp#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Savant Capital, LLC | 1,443,868 | New | 2.44% | $8 M | Nov 6, 2026 |
| 2 | Vanguard Capital Management LLC | 115,221 | New | 0.19% | $1 M | Nov 13, 2026 |
| 3 | Geode Capital Management, LLC | 28,724 | New | 0.05% | $0 M | Nov 6, 2026 |
| 4 | State Street Corp | 14,900 | New | 0.03% | $0 M | Nov 12, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 13,770 | New | 0.02% | $0 M | Nov 13, 2026 |
| 6 | BlackRock, Inc. | 11,878 | New | 0.02% | $0 M | Nov 13, 2026 |
| 7 | Discovery Capital Management, LLC / CT | 11,225 | New | 0.02% | $0 M | Nov 16, 2026 |
| 8 | PNC Financial Services Group, Inc. | 10,333 | New | 0.02% | $0 M | Nov 6, 2026 |
| 9 | UBS Group AG | 2,079 | New | 0.00% | $0 M | Nov 10, 2026 |
| 10 | Tower Research Capital LLC (TRC) | 1,630 | New | 0.00% | $0 M | Nov 16, 2026 |
| 11 | Morgan Stanley | 1,183 | New | 0.00% | $0 M | Nov 13, 2026 |
| 12 | Royal Bank Of Canada | 73 | New | 0.00% | $0 M | Nov 16, 2026 |
| 13 | SBI Securities Co., Ltd. | 15 | New | 0.00% | $0 M | Oct 22, 2026 |
Insider trading at OneMedNet Corp#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jeffrey YuChief Medical Officer, Director, 10% owner | Buy | +45,126 | $5.540 | $250 K | 896,840 | Form 4 |
| filed | Thomas KosasaDirector, 10% owner | Buy | +129,758 | $5.780 | $750 K | 1.98 M | Form 4 |
| filed | Aaron GreenChief Executive Officer, Director | Sell | -1,667 | $6.480 | $11 K | 247,971 | Form 4 |
| filed | Aaron GreenChief Executive Officer, Director | Sell | -5,000 | $7.392 | $37 K | 249,638 | Form 4 |
| filed | Robert Lawrence GoldenChief Financial Officer, Director | Sell | -3,000 | $6.630 | $20 K | 91,291 | Form 4 |
| filed | Robert Lawrence GoldenChief Financial Officer, Director | Sell | -3,000 | $6.300 | $19 K | 94,291 | Form 4 |
| filed | Robert Lawrence GoldenChief Financial Officer, Director | Sell | -2,500 | $6.600 | $17 K | 97,291 | Form 4 |
| filed | Jeffrey YuChief Medical Officer, Director, 10% owner | Buy | +142,857 | $0.630 | $90 K | 8.92 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: OneMedNet Corp#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-11-09 14:32 UTC, code LUDP, resumed 14:37 UTC
- 2026-09-28 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 46 shares at $4.37
- : 2 shares at $4.46
- : 2,424 shares at $4.38
- : 3 shares at $4.57
- : 1,240 shares at $4.66
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
OneMedNet Corp scorecard#
Passes 4 of the 19 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 14, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median163.6×Price to sales 163.6× against Diagnostics and Research's median of 4.5×.
- ✗Free cash flow yield above 5%-3.2%Free cash flow is -3.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 4
- ✓Revenue grew in the newest year112.5%Revenue up 112.5% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years5.8%5.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median5.8%5.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.06 vs -0.36Diluted EPS -0.06 in fiscal 2025 against -0.36 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-711.0%-711.0% against Diagnostics and Research's median of -2.4% (66 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-711.0%-711.0% in fiscal 2025 against -671.3% in 2022.
Financial health1 of 5
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.44 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $0 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-138.1×Operating income -138.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-55.90Z-score -55.90 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year58.7%Diluted shares up 58.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from OneMedNet Corp's statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -711.0% | -2.4% | |
| Net margin | -205.9% | -3.6% | |
| Revenue growth, 3 years a year | 5.8% | 3.6% | |
| Revenue growth | 112.5% | 6.6% | |
| Free cash flow margin | -552.2% | 4.7% |
5of 9on the Piotroski tests of financial strength
- Net loss of $3 million, the 4th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- The share count rose 58.7% in the year.
- Shareholders' equity is negative: -$3 million.
OneMedNet Corp: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 1.4+111%100% | 0.6−37.0%100% | 1.0r1.0−11.4%100% | 1.2r1.2—100% | |
| Cost of revenue | 1.9+102%137% | 0.9−19.7%144% | 1.2r1.1−24.0%113% | 1.5r1.5—131% | |
| Gross profit | −0.5—−37.0% | −0.3—−43.7% | −0.1r−0.1—−12.6% | −0.4r−0.4—−31.2% | |
| Research and development | 1.5+3.3%111% | 1.5−29.0%228% | 2.1r1.6+29.8%202% | 1.6r1.0—138% | |
| Selling and marketing | 1.3+53.3%93.6% | 0.8−25.6%129% | 1.1r1.1+16.4%109% | 1.0r1.0—83.1% | |
| General and administrative | 6.4−9.3%469% | 7.0+98.3%1093% | 3.5r5.3−26.3%347% | 4.8r8.8—417% | |
| Operating expenses | 9.2−1.7%674% | 9.3+38.7%1450% | 6.7r8.2−8.6%659% | 7.4r11—638% | |
| Operating income | −9.7—−711% | −9.6—−1494% | −6.9r−8.4—−671% | −7.7r−5.3—−669% | |
| Interest expense and finance costs | 0.1−54.4%4.9% | 0.1+1236%22.9% | 0.0r0.7−97.3%1.1% | 0.4—35.0% | |
| Other non-operating income (expense) | 6.9—505% | −0.5—−81.2% | −27r−15—−2636% | −23r5.2—−1970% | |
| Income before tax | −2.8—−206% | −10—−1575% | −34—−3307% | −30r0.6—−2640% | |
| Income tax | 0.0−50.0%0.1% | 0.0−88.9%0.3% | 0.0+5.9%1.8% | 0.0r0.2—1.5% | |
| Income from continuing operations | −2.8—−206% | −10—−1571% | — | — | |
| Net income including minority interests | — | — | — | 0.3—29.2% | |
| Net income attributable to shareholders | −2.8—−206% | −10—−1575% | −34r−23—−3309% | −30r0.3—−2641% | |
| Earnings per share, basic | -0.06—— | -0.36—— | -4.65r-0.98—— | -7.66—— | |
| Earnings per share, diluted | -0.06—— | -0.36—— | -4.65r-0.98—— | -7.66r0.03—— | |
| Shares, weighted average (basic) | 45+58.7%— | 28+286%— | 7.3r24+83.0%— | 4.0—— | |
| Shares, weighted average (diluted) | 45+58.7%— | 28+286%— | 7.3r24+83.0%— | 4.0—— | |
| Balance sheet | |||||
| Cash and cash equivalents | 0.6+240%27.2% | 0.2+266%4.6% | 0.0r0.0−82.7%10.1% | 0.3r0.0—21.0% | |
| Receivables | 0.5+132%23.0% | 0.2+40.1%5.7% | 0.2r0.2+700%32.8% | 0.0r0.0—1.5% | |
| Other current assets | 0.5+32.2%23.7% | 0.4+132%10.3% | 0.2r0.2+64.4%35.8% | 0.1r0.1—7.8% | |
| Current assets | 2.1−42.1%97.4% | 3.6+892%97.1% | 0.4r0.4−6.6%78.7% | 0.4r0.0—30.3% | |
| Property, plant and equipment | 0.1−48.1%2.6% | 0.1+9.1%2.9% | 0.1r0.1+19.3%21.3% | 0.1r0.1—6.4% | |
| Total assets | 2.2−42.3%100% | 3.7+703%100% | 0.5r0.5−64.0%100% | 1.3r29—100% | |
| Accounts payable | 3.2−47.0%149% | 6.0r6.4+29.0%162% | 4.7r4.2+298%1009% | 1.2r1.1—91.3% | |
| Debt due within a year | 1.0−89.6%45.3% | 9.4—252% | — | — | |
| Current liabilities | 4.8−74.9%224% | 19+39.0%516% | 14r13−47.0%2982% | 26r2.0—2025% | |
| Total liabilities | 5.1−74.0%238% | 20+41.5%528% | 14r13−49.7%2997% | 28r9.1—2145% | |
| Retained earnings | −104—−4852% | −102—−2725% | −91r−55—−19707% | −58r−12—−4473% | |
| Shareholders' equity | −3.0—−138% | −16—−428% | −13r−13—−2897% | −26r−8.8—−2045% | |
| Total liabilities and equity | 2.2−42.3%100% | 3.7+703%100% | 0.5r0.5−64.0%100% | 1.3r29—100% | |
| Shares outstanding | 52r52+85.1%— | 28+18.7%— | 24+484%— | 4.0r4.6—— | |
| Cash-flow statement | |||||
| Depreciation and amortization | 0.1+14.0%4.8% | 0.1+104%8.9% | 0.0r0.0+12.0%2.7% | 0.0r0.0—2.2% | |
| Share-based compensation | 2.0+224%150% | 0.6−57.4%97.7% | 1.5−20.9%144% | 1.9r2.8—162% | |
| Cash from operating activities | −7.5—−552% | −7.0r−7.0—−1081% | −4.8r8.2—−469% | −4.7r−0.9—−408% | |
| Capital expenditure | −0.0—−1.0% | −0.1—−7.9% | −0.0r−0.0—−4.3% | −0.1r−0.1—−5.0% | |
| Cash from investing activities | 2.3—170% | −2.0—−308% | −0.0—−4.3% | −0.1r−2.2—−5.0% | |
| Debt repaid | — | −0.2—−31.1% | — | — | |
| Cash from financing activities | 5.6−38.1%413% | 9.1r9.1+96.5%1409% | 4.6r−8.4+6.4%452% | 4.3r2.8—376% | |
| Change in cash | 0.4+230%30.4% | 0.1—19.4% | −0.2r−0.3—−21.9% | −0.4r−0.4—−37.1% | |
| Report | 10-K | 10-K | 10-K | 10-K/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 1.5+217%100% | 0.3+88.4%100% | 0.1−29.9%100% | 0.9*+3327%100% | 0.2+24.6%100% | 0.2−31.7%100% | 0.1−44.8%100% | 0.0*−92.4%100% | 0.1−56.4%100% | 0.2—100% | 0.2—100% | 0.3r0.3*—100% | 0.3—100% | |
| Cost of revenue | 2.5+137%169% | 0.9+116%293% | 0.5+31.9%496% | 0.7*+1296%81.5% | 0.4+76.5%225% | 0.4+20.4%255% | 0.4+13.9%264% | 0.1*−84.6%200% | 0.2−22.9%159% | 0.3—145% | 0.3—128% | 0.3r0.3*—99.4% | 0.3—89.9% | |
| Gross profit | −1.0—−68.8% | −0.6—−193% | −0.4—−396% | 0.2*—18.5% | −0.2—−125% | −0.2—−155% | −0.2—−164% | −0.0*−1400%−100% | −0.1−355%−59.2% | −0.1—−44.9% | −0.1—−27.8% | 0.0r0.0*—0.6% | 0.0—10.1% | |
| Research and development | 1.4+2.4%96.2% | 0.3−15.2%111% | 0.3−10.6%324% | 0.4*+30.3%49.7% | 0.3+8.4%182% | 0.4−0.3%246% | 0.3−21.8%254% | 0.3*−31.9%1308% | 0.3−26.4%210% | 0.4—169% | 0.4—179% | 0.5r0.5*—147% | 0.4—124% | |
| Selling and marketing | 1.5+67.7%103% | 0.4+52.1%134% | 0.4+30.3%394% | 0.4*+106%47.8% | 0.3+117%172% | 0.3+1.6%166% | 0.3+26.6%212% | 0.2*−31.5%796% | 0.1−42.4%98.6% | 0.3—111% | 0.2—92.3% | 0.3r0.3*—88.8% | 0.2—74.5% | |
| General and administrative | 6.2−4.2%428% | 1.0−17.1%336% | 1.5+8.9%1545% | 2.4*+11.0%267% | 1.4−23.6%783% | 1.2−31.1%763% | 1.4+0.3%994% | 2.1r2.1*+100%8242% | 1.8r1.9+38.3%1277% | 1.7—756% | 1.4—548% | 1.1r3.1*—314% | 1.3—402% | |
| Operating expenses | 9.1+4.2%627% | 1.7−6.9%581% | 2.2+8.6%2263% | 3.2*+20.7%364% | 2.0−10.6%1137% | 1.8−22.5%1175% | 2.0−1.6%1460% | 2.7r2.6*+43.9%10346% | 2.3r2.3+14.9%1586% | 2.4—1036% | 2.0—819% | 1.9r4.0*—550% | 2.0—601% | |
| Operating income | −10—−696% | −2.3—−774% | −2.6—−2658% | −3.1*—−346% | −2.2—−1263% | −2.1—−1331% | −2.2—−1623% | −2.7r−2.7*—−10446% | −2.3r−2.4—−1645% | −2.5—−1081% | −2.1—−847% | −1.9r−6.8*—−549% | −1.9r−0.9—−591% | |
| Interest expense and finance costs | 0.0−64.9%2.3% | 0.0−59.1%3.1% | 0.0−67.7%10.4% | 0.0*−70.4%0.9% | 0.0−57.1%3.4% | 0.0+46.7%14.2% | 0.0+24.0%22.6% | 0.0*—104% | 0.0—9.9% | 0.0—6.6% | 0.0—10.1% | — | — | |
| Other non-operating income (expense) | 1.6−72.9%112% | 0.1−98.2%30.5% | 0.1−69.3%103% | −0.1*−117%−6.4% | 1.5+437%844% | 5.0—3255% | 0.3—235% | 0.3r0.3*—1327% | 0.3r0.3—196% | −1.1—−500% | −0.0—−3.2% | −0.6r−14*—−179% | −12—−3654% | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | −33*—−9725% | −0.7—−224% | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | −0.2*—−56.5% | 0.1—26.9% | |
| Income from continuing operations | −3.2—−220% | −2.3—−788% | −2.5—−2604% | 3.8*—426% | −2.2—−1243% | −2.1—−1355% | −1.9—−1387% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −8.5—−584% | −2.2−173%−744% | −2.5—−2555% | −3.1*—−352% | −0.7—−419% | 3.0—1924% | −1.9—−1388% | −2.4r−2.4*—−9127% | −2.1—−1449% | −3.6—−1581% | −2.1—−850% | −2.5r−22*—−734% | −14r−1.7—−4245% | |
| Earnings per share, basic | — | -0.04−157%— | -0.04—— | — | -0.01—— | 0.07—— | -0.06—— | — | -0.07—— | -0.14r-0.15—— | -0.08r-0.09—— | — | -3.23—— | |
| Earnings per share, diluted | — | -0.04−157%— | -0.04—— | — | -0.01—— | 0.07—— | -0.06—— | — | -0.07—— | -0.14r-0.15—— | -0.08r-0.09—— | — | -3.23—— | |
| Shares, weighted average (basic) | 58+57.5%— | 58+57.5%— | 55+62.2%— | — | 53+79.8%— | 37+46.3%— | 34+36.8%— | — | 29r28+584%— | 25r24—— | 25r24—— | — | 4.3—— | |
| Shares, weighted average (diluted) | 58+51.1%— | 58+51.1%— | 55+62.2%— | — | 53+79.8%— | 38+52.5%— | 34+36.8%— | — | 29r28+584%— | 25r24—— | 25r24—— | — | 4.3—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.4—26.2% | 0.4+193%26.2% | 0.2+61.8%15.5% | 0.6+240%27.2% | 0.1−92.3%9.9% | 0.1−70.0%5.2% | 0.1−17.2%8.3% | 0.2+266%4.6% | 1.9+216%44.1% | 0.4—39.1% | 0.2—23.2% | 0.0r0.0—10.1% | 0.6—3.2% | |
| Receivables | 0.7—48.7% | 0.7+161%48.7% | 0.7+182%46.3% | 0.5+132%23.0% | 0.6+824%38.6% | 0.3+239%10.9% | 0.2−2.4%14.3% | 0.2+40.1%5.7% | 0.1−27.1%1.4% | 0.1—7.2% | 0.3—33.7% | 0.2r0.2—32.8% | 0.1—0.4% | |
| Other current assets | 0.3—21.3% | 0.3−0.7%21.3% | 0.5+3.8%30.8% | 0.5+32.2%23.7% | 0.1−23.8%7.6% | 0.3+68.4%12.5% | 0.4+95.2%25.8% | 0.4+132%10.3% | 0.2+72.8%3.4% | 0.2—16.7% | 0.2—30.5% | 0.2r0.2—35.8% | 0.1—0.5% | |
| Current assets | 1.3—96.3% | 1.3−42.1%96.3% | 1.5−10.5%96.9% | 2.1−42.1%97.4% | 1.4−66.4%96.0% | 2.3+137%97.0% | 1.6+149%94.2% | 3.6+892%97.1% | 4.3+18502%98.1% | 1.0—91.8% | 0.7—87.5% | 0.4r0.4—78.7% | 0.0r2.8—0.1% | |
| Property, plant and equipment | 0.1—3.7% | 0.1−27.1%3.7% | 0.0−53.5%3.1% | 0.1−48.1%2.6% | 0.1−28.6%4.0% | 0.1−17.6%3.0% | 0.1+7.4%5.8% | 0.1+9.1%2.9% | 0.1−98.3%1.9% | 0.1—8.2% | 0.1—12.5% | 0.1r0.1—21.3% | 5.0r0.1—25.9% | |
| Total assets | 1.4—100% | 1.4−41.6%100% | 1.5−13.0%100% | 2.2−42.3%100% | 1.5−65.7%100% | 2.3+124%100% | 1.7+131%100% | 3.7+703%100% | 4.4−77.3%100% | 1.0—100% | 0.8—100% | 0.5r0.5—100% | 19r2.9—100% | |
| Accounts payable | 3.5—255% | 3.5+167%255% | 3.9−42.6%262% | 3.2−47.0%149% | 3.2−48.1%212% | 1.3−79.9%55.6% | 6.9+16.9%397% | 6.0r6.4+29.0%162% | 6.2+318%140% | 6.5—622% | 5.9—783% | 4.7r4.2—1009% | 1.5—7.6% | |
| Debt due within a year | 0.7—51.4% | 0.7—51.4% | 0.8—55.5% | 1.0−89.6%45.3% | — | — | — | 9.4—252% | — | — | — | — | — | |
| Current liabilities | 4.7—346% | 4.7−23.3%346% | 5.4−70.5%355% | 4.8−74.9%224% | 5.0−73.1%332% | 6.2−69.3%264% | 18+23.9%1048% | 19+39.0%516% | 19+505%425% | 20—1926% | 15—1954% | 14r13—2982% | 3.1r14—15.9% | |
| Total liabilities | 4.9—358% | 4.9−21.0%358% | 5.6−69.4%371% | 5.1−74.0%238% | 5.4−70.8%362% | 6.2−69.5%264% | 18+11.1%1056% | 20+41.5%528% | 19+58.9%425% | 20—1943% | 16—2193% | 14r13—2997% | 12r18—60.8% | |
| Retained earnings | −109—−7991% | −109—−7991% | −107—−7088% | −104—−4852% | −101—−6722% | −100—−4300% | −103—−5974% | −102—−2725% | −99—−2261% | −97—−9331% | −94—−12473% | −91r−55—−19707% | −13r−37—−64.9% | |
| Shareholders' equity | −3.5—−258% | −3.5—−258% | −4.1—−271% | −3.0—−138% | −3.9—−262% | −3.8—−164% | −17—−956% | −16—−428% | −14—−325% | −19—−1843% | −16—−2093% | −13r−13—−2897% | −48r−15—−247% | |
| Total liabilities and equity | 1.4—100% | 1.4−41.6%100% | — | 2.2−42.3%100% | 1.5−65.7%100% | 2.3+124%100% | 1.7+131%100% | 3.7+703%100% | 4.4−77.3%100% | 1.0—100% | 0.8—100% | 0.5r0.5—100% | 19r2.9—100% | |
| Shares outstanding | 58—— | 58+25.2%— | 53+72.7%— | 52r52+85.1%— | 50+77.7%— | 46+93.2%— | 31+29.2%— | 28+18.7%— | 28+515%— | 24—— | 24—— | 24—— | 4.6—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | 0.0−8.3%11.5% | 0.0*−65.4%1.0% | 0.0*0.0%5.6% | 0.0*+240%21.9% | 0.0+9.1%8.8% | 0.0*+189%100% | 0.0*+66.7%7.0% | 0.0*—4.4% | 0.0—4.4% | 0.0r0.0*—2.6% | 0.0r0.0*—1.8% | |
| Share-based compensation | 2.5+218%173% | 0.5*+135%159% | 0.4+107%449% | 1.5*+720%167% | 0.1−31.4%80.2% | 0.2+91.3%127% | 0.2+51.8%152% | 0.2*+524%696% | 0.2−74.1%146% | 0.1—45.4% | 0.1—55.2% | 0.0r0.6*—8.5% | 0.8—245% | |
| Cash from operating activities | −6.9—−472% | −1.9*—−642% | −1.5—−1606% | −1.7*—−192% | −1.7r−1.6*—−987% | −2.2r−2.3*—−1412% | −1.9r−1.9—−1353% | −2.0r−2.0*—−7677% | −1.9*—−1340% | −1.5*—−663% | −1.5—−624% | −1.7r9.0*—−507% | −1.1r−4.1*—−337% | |
| Capital expenditure | −0.0—−1.1% | −0.0*—−3.1% | −0.0—−2.1% | −0.0*—−0.6% | 0*—0.0% | −0.0*—−1.9% | −0.0—−3.6% | −0.0*—−135% | −0.0*—−6.3% | −0.0*—−0.4% | −0.0—−2.4% | −0.0r−0.0*—−4.7% | −0.0r−0.0*—−6.4% | |
| Cash from investing activities | 1.5—101% | 0.1*—19.2% | 0.4−81.7%367% | −0.1*−114%−5.7% | 1.1*—626% | −0.7*—−432% | 1.9—1401% | 0.4*—1404% | −2.3*—−1648% | −0.0*—−0.4% | −0.0—−2.4% | −0.0r−11*—−4.7% | −0.0r11*—−6.4% | |
| Debt repaid | — | — | — | — | — | — | — | 0*—0.0% | −0.1*—−70.4% | — | — | — | — | |
| Shares issued | — | — | — | — | 0.5*—282% | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 5.6−30.1%388% | 1.9*−31.5%666% | 0.8—873% | 2.2*—247% | 0.7r0.5*−87.8%376% | 2.8r3.0*+39.1%1830% | −0.1−106%−68.6% | −0.1r−0.1*−111%−504% | 5.5*+285%3852% | 2.0*—899% | 1.7—677% | 1.2r1.6*—346% | 1.4r4.2*—436% | |
| Change in cash | 0.2—16.2% | 0.1*—42.8% | −0.4—−367% | 0.4*—48.9% | 0.0*−97.8%15.3% | −0.0*−104%−14.2% | −0.0−122%−20.4% | −1.8*—−6777% | 1.2*+309%864% | 0.5*—235% | 0.1—51.2% | −0.6r−0.2*—−166% | 0.3r0.4*—92.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What OneMedNet Corp sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Data Delivery Revenue$1 M92%+331%
- Subscription Revenue$0 M7.7%-71%
Countries and regions
- EMEA$1 M51%+192%
- Americas$1 M45%+52%
- Asia Pacific$0 M4.1%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at OneMedNet Corp#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 4 · Directors and officers 4 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 2
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How OneMedNet Corp compares in Diagnostics and Research
- Market cap$237 M · higher than 34% of 110
- Revenue$1 M · higher than 6% of 123
- Net margin-586.2% · higher than 2% of 112
- Revenue growth112.5% · higher than 95% of 89
- Price / sales163.6× · lower than 2% of 85
- FCF yield-3.2% · higher than 45% of 66
- 🇮🇳 Vimta Labs Limited$226 M
- 🇺🇸 Exagen Inc.$218 M
- 🇨🇦 Spectral Medical Inc.$217 M
- 🇺🇸 Biodesix, Inc.$265 M
- 🇨🇳 Dirui Industrial Co., Ltd.$336 M
- 🇺🇸 Neuronetics, Inc.$162 M
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| OneMedNet Corp🇬🇧 | $237 M | — | -586.2% | +112.5% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Vimta Labs Limited$226 M
- Exagen Inc.$218 M
- Spectral Medical Inc.$217 M
- Biodesix, Inc.$265 M
- Dirui Industrial Co., Ltd.$336 M
- Neuronetics, Inc.$162 M
Sources and freshness
- Market cap:
- Oct 14, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, SEC annual report, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at OneMedNet Corp? Verify and update this profile — free
Show OneMedNet Corp's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.